Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Cancer immunotherapy has emerged as an effective therapy in a variety of cancers. However, a key challenge in the field is that only a subset of patients who receive immunotherapy exhibit durable response. It has been hypothesized that host genetics influences the inherent immune profiles of patients and may underlie their differential response to immunotherapy. Herein, we systematically determined the association of common germline genetic variants with gene expression and immune cell infiltration of the tumor. We identified 64,094 expression quantitative trait loci (eQTLs) that associated with 18,210 genes (eGenes) across 24 human cancers. Overall, eGenes were enriched for their being involved in immune processes, suggesting that expression of immune genes can be shaped by hereditary genetic variants. We identified the endoplasmic reticulum aminopeptidase 2 ( ERAP2 ) gene as a pan-cancer type eGene whose expression levels stratified overall survival in a subset of patients with bladder cancer receiving anti–PD-L1 (atezolizumab) therapy. Finally, we identified 103 gene signature QTLs (gsQTLs) that were associated with predicted immune cell abundance within the tumor microenvironment. Our findings highlight the impact of germline SNPs on cancer-immune phenotypes and response to therapy; and these analyses provide a resource for integration of germline genetics as a component of personalized cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 2×
“The rapidly emerging field of cancer immunotherapy aims to tip the balance by harnessing the host immune response(s); however, despite significant successes, only a subset of patients benefits from durable responses (3).”
BackgroundSelf-citationThe Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
The GTEx Consortium, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young, T. R., Gelfand, E. T., Trowbridge, C. A., Maller, J. B., Tukiainen, T., et al. (2015) · Science · doi:10.1126/science.1262110 · Cited by 5,062
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722
xCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397
Genetic effects on gene expression across human tissues
GTEx Consortium (2017) · Nature · doi:10.1038/nature24277 · Cited by 4,036
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 2×
“Indeed, IFNγ–induced genes, including CXCL9, have been shown to be associated with both enhanced CD8 T cell infiltration in tumors and response to anti–PD-L1 (30).”
BackgroundMethodSelf-citationSuper-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · cited 1×
“We performed our analyses using SNP-gene pair P values computed from bladder urothelial carcinoma (BLCA) and lung adenocarcinoma (LUAD), where enhancer annotations were available for the corresponding healthy tissue (21).”
MethodLiu, J. Z., van Sommeren, S., Huang, H., Ng, S. C., Alberts, R., Takahashi, A., Ripke, S., Lee, J. C., Jostins, L., Shah, T., et al. (2015) · Nature Genetics · doi:10.1038/ng.3359 · Cited by 2,603
Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., Lees, C. W., Balschun, T., Lee, J., Roberts, R., et al. (2010) · Nature Genetics · doi:10.1038/ng.717 · Cited by 2,520
Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074950 · Cited by 2,309
Matrix eQTL: ultra fast eQTL analysis via large matrix operations
Shabalin, A. A. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts163 · Cited by 1,694
Systematic identification of trans eQTLs as putative drivers of known disease associations
Westra, H.-J., Peters, M. J., Esko, T., Yaghootkar, H., Schurmann, C., Kettunen, J., Christiansen, M. W., Fairfax, B. P., Schramm, K., Powell, J. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2756 · Cited by 1,658
de Lange, K. M., Moutsianas, L., Lee, J. C., Lamb, C. A., Luo, Y., Kennedy, N. A., Jostins, L., Rice, D. L., Gutierrez-Achury, J., Ji, S.-G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3760 · Cited by 1,445
Understanding mechanisms underlying human gene expression variation with RNA sequencing
Pickrell, J. K., Marioni, J. C., Pai, A. A., Degner, J. F., Engelhardt, B. E., Nkadori, E., Veyrieras, J.-B., Stephens, M., Gilad, Y., & Pritchard, J. K. (2010) · Nature · doi:10.1038/nature08872 · Cited by 1,256
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Stegle, O., Parts, L., Piipari, M., Winn, J., & Durbin, R. (2012) · Nature Protocols · doi:10.1038/nprot.2011.457 · Cited by 1,049
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Saveanu, L., Carroll, O., Lindo, V., Del Val, M., Lopez, D., Lepelletier, Y., Greer, F., Schomburg, L., Fruci, D., Niedermann, G., et al. (2005) · Nature Immunology · doi:10.1038/ni1208 · Cited by 481 · cited 2×
“It is precarious to draw inferences from mouse models due to the presence of two ERAP genes in humans compared with one gene in mice (24).”
BackgroundGenetic adaptation and Neandertal admixture shaped the immune system of human populations
Quach, H., Rotival, M., Pothlichet, J., Loh, Y.-H. E., Dannemann, M., Zidane, N., Laval, G., Patin, E., Harmant, C., Lopez, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.024 · Cited by 475 · cited 1×
“These findings are consistent with previous studies, which reported that genetic variants play a major role in shaping an individual’s immune response (8, 20).”
ResultSelf-citationCancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Vesely, M. D., & Schreiber, R. D. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12105 · Cited by 367 · cited 1×
“The host immune system counteracts cancer by recognizing, targeting, and eliminating tumor cells, but, in doing so, applies the selective pressure responsible for tumor immune evasion (2).”
BackgroundA Functional Genomics Approach to Understand Variation in Cytokine Production in Humans
Li, Y., Oosting, M., Smeekens, S. P., Jaeger, M., Aguirre-Gamboa, R., Le, K. T. T., Deelen, P., Ricaño-Ponce, I., Schoffelen, T., Jansen, A. F. M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.10.017 · Cited by 324
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P., & Allison, J. P. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130590 · Cited by 300 · cited 1×
“Additionally, activating ICOS has been shown to enhance tumor immunity in mice (29), and agonist antibodies are being developed for cancer immunotherapy in humans (27).”
BackgroundRoederer, M., Quaye, L., Mangino, M., Beddall, M. H., Mahnke, Y., Chattopadhyay, P., Tosi, I., Napolitano, L., Terranova Barberio, M., Menni, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.046 · Cited by 296 · cited 1×
“2% (5,322) being identified in only one cancer type (Fig.”
BackgroundDuffy, D., Rouilly, V., Libri, V., Hasan, M., Beitz, B., David, M., Urrutia, A., Bisiaux, A., LaBrie, S. T., Dubois, A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.002 · Cited by 242 · cited 1×
“Indeed, there is large variation in the abundance and activation state of multiple immune cell types (4–6), molecules (7, 8), and genes (9, 10), which likely translates to distinct immune states.”
BackgroundSelf-citation
Cited by
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Advances in bladder cancer biology and therapy
Tran, L., Xiao, J.-F., Agarwal, N., Duex, J. E., & Theodorescu, D. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00313-1 · Cited by 735
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Matson, V., Chervin, C. S., & Gajewski, T. F. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.041 · Cited by 385
A proteogenomic portrait of lung squamous cell carcinoma
Satpathy, S., Krug, K., Jean Beltran, P. M., Savage, S. R., Petralia, F., Kumar-Sinha, C., Dou, Y., Reva, B., Kane, M. H., Avanessian, S. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.016 · Cited by 377
Metadata
- Authors
- Lim, Y. W., Chen-Harris, H., Mayba, O., Lianoglou, S., Wuster, A., Bhangale, T., Khan, Z., Mariathasan, S., Daemen, A., Reeder, J., Haverty, P. M., Forrest, W. F., Brauer, M., Mellman, I., & Albert, M. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2018-11-21
- Volume
- 115
- Issue
- 50
- Pages
- E11701-E11710
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2901917129
- Cited by
- 121
- References
- 24
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.